

Draft Manuscript for Review

"The Impact of NF- κ B and Keap1/Caspase-3 Signaling Pathway on protective Effects of sitagliptin in a Rat Model of Doxorubicin-Induced Cardiac Dysfunction."

Mahmoud M. Hassan^{1*}, Enas M. Kasem¹, Walaa H. Mohammed¹, Manar A. Elkholy², Alzahraa Z. Elsayed²,
Eman Mohamed Faruk^{3,4}, Mona K. Alawam¹

¹ Department of Physiology, Faculty of Medicine, Benha University, Qalubiya, Egypt.

² Department of Pharmacology, Faculty of Medicine, Benha University, Qalubiya, Egypt.

³ Anatomy Department, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.

⁴ Department of Histology and Cell Biology, Faculty of Medicine, Benha University Benha, Egypt

Journal:	Bulletin of Egyptian Society for Physiological Sciences
Manuscript ID:	BESPS-2502-1204 (R1)
Manuscript Title:	The Impact of NF- κ B and Keap1/Caspase-3 Signaling Pathway on protective Effects of sitagliptin in a Rat Model of Doxorubicin-Induced Cardiac Dysfunction.

Peer Review

Thank you for the opportunity to review and revise our manuscript. We appreciate the reviewers' valuable feedback and have made the necessary corrections accordingly. Below are our responses to the reviewer's comments:

1. **Page 4, Line 38:** Yes, we meant each group consisted of 4 rats. We have clarified this in the revised manuscript.
2. **Number of Rats:** We acknowledge the inconsistency in the total number of rats mentioned. We have corrected the text to ensure the numbers are accurate and consistent throughout the manuscript as the number is 6 rats each group.

Reference 9: We have provided an accessible link for Reference 9. <http://doi:10.4172/2167-065X.1000174>, 2017.

https://www.omicsonline.org/open-access/comparative-study-of-the-protective-effect-of-metformin-and-sitagliptinagainst-doxorubicininduced-cardiotoxicity-in-rats-2167-065X-1000174.php?aid=93734&utm_source=chatgpt.com

3. **Reference 10:** We have changed this reference and ensured it contains the correct dose of STG.
4. **Reference 11:** We have updated this reference to include the correct dose of DOX.
5. **ECG Electrode Placement:** We appreciate this correction. We have revised the description to accurately reflect the standard **Lead II configuration**, with the **positive electrode placed on the left hind limb**.
6. **ECG Measurement Reference:** We have added an appropriate reference for ECG measurement.
7. **ABP Measurement Reference:** We have included a relevant reference for ABP measurement.
8. **PCR Gene Sequence Reference:** We have added a citation for the PCR gene sequences used in our study.
9. **Reference Formatting:** We have reformatted all references according to the journal's style guide, ensuring consistency and accuracy.

We appreciate the reviewers' insightful comments, which have helped improve the clarity and rigor of our manuscript. Please let us know if further modifications are required.

Best regards,

The Impact of NF-κB and Keap1/Caspase-3 Signaling Pathway on protective Effects of sitagliptin in a Rat Model of Doxorubicin-Induced Cardiac Dysfunction

Abstract:

Background: Doxorubicin (DOX) treatment is a primary cause of chemotherapy-induced cardiotoxicity. Antidiabetic sitagliptin (STG) has been shown to improve cardiovascular functions through anti-inflammatory, antioxidant, and anti-apoptotic effects. Oxidative stress plays a crucial role in the development of various cardiovascular diseases, especially those related to endothelial dysfunction. The transcription factor nuclear factor erythroid-2-like 2 (Nrf2) is the main regulator of antioxidant defense mechanisms. Nrf2, along with its suppressor protein Kelch-like ECH-associated protein 1 (Keap1), controls the levels of reactive oxygen species (ROS). **Objective:** This study aimed to evaluate the role of the Nrf2/caspase-3 signaling pathway in the cardiotoxic effect of DOX and the potential role of sitagliptin (STG). **Materials and Methods:** Rats were divided into four groups, each comprising eight animals (n=8): a control group, an STG group (receiving 10 mg/kg/day for 21 days), a DOX group (receiving 1mg/kg i.p per day for five injections \ week for 3 weeks) and STG+DOX group (treated by STG and DOX as previously mentioned). **Results:** The effect of DOX on cardiac tissue detected a significant reduction in ABP and deviated ST segment, while STG improved DOX-induced cardiotoxicity markers, oxidative stress, and inflammatory markers. Also, STG regulates cardiovascular hemodynamics and reduces both cardiac caspase-3 and Keap-1, and upregulates Nrf2 gene expression levels. **Conclusion:** STG administration can exert protective effects against doxorubicin-induced cardiac toxicity through anti-inflammatory, antioxidant, and anti-apoptotic properties, in addition to promoting the Nrf2 signaling pathway.

Keywords: cardiac toxicity, nuclear factor erythroid 2-related factor 2 (Nrf2), Doxorubicin, caspase-3

1. INTRODUCTION:

DOX is a chemotherapy drug that is commonly used to treat various types of cancers, including ovarian, thyroid, gastric, leukemia, and breast cancers [1]. Although Dox has been proven to increase the survival rate of

cancer patients, Dox-induced cardiac toxicity (DIC) has been recognized as a complication of chemotherapy. Patients with childhood cancer and those treated with DOX have a high risk of developing symptomatic cardiac dysfunction at an early stage, and this risk remains high for years after treatment [2].

The antitumor activity of doxorubicin, through direct DNA damage, interferes with the function of many enzymes necessary for DNA replication [2]. The mechanisms to explain doxorubicin-induced cardiotoxicity are not completely clear. It seems to be a multi-step process, with different potential pathways involved that lead to cardiomyocyte death [3]. The main mechanisms that have been proposed by various research groups include oxidative stress, lipid peroxidation, Ca^{2+} homeostasis dysregulation, iron metabolism defect, gene expression modulation, and activation of several programmed cell death pathways leading to cardiomyocyte loss. Therefore, doxorubicin causes severe cardiotoxicity that is dose-dependent and frequently leads to dilated cardiomyopathy, systolic cardiac dysfunction, and, in severe cases, heart failure, all of which have a major detrimental effect on the patient's health and present a major obstacle to the clinical use of doxorubicin. Various strategies have been tested in both the prevention and treatment of doxorubicin-induced cardiotoxicity to improve the quality of life of cancer survivors [4].

STG is a highly selective DPP-4 inhibitor. Its major application is in the treatment of type 2 diabetes [5]. It has an anti-diabetic effect on the blood. by preventing the DPP4 enzyme from degrading glucagon-like peptide 1 (GLP-1), GLP-1 analogs have recently been demonstrated to be helpful during ischemia-reperfusion (I/R) injury in both clinical and animal models by improving cardiac function, enhancing myocardial glucose uptake, and limiting infarct size. increase of myocardial glucose uptake and improvement in cardiac function.

STG exerts a protective effect on the heart function. It has been found to protect the heart from ROS. It has an important role in the regulation of defensive genes activation and induction of antioxidant enzymes as SOD and glutathione peroxidase leading to suppression of injury evoked by ROS and protection of cells against oxidative stress injurious effects [6].

The role of caspases in programmed cell death has been reviewed many times. It is widely accepted that, in mammals, two main pathways have evolved to activate the caspase cascade. The mitochondrial pathway (intrinsic pathway) and the death receptor pathway (extrinsic pathway). The release of pro-apoptotic proteins, including cytochrome c, from the inter-membrane space into the cytoplasm [7]. Cytochrome c can then bind Apaf-1, forming the apoptosome and activating caspase-9. Once active, caspase-9 can directly cleave and activate caspase-3 and caspase-7. [8]. This study was designed to demonstrate the effect of STG on DOX-induced cardiotoxicity in adult male rats.

2. MATERIAL AND METHODS:

2.1. Chemical used:

DOX, provided as ampoules (D-RUBILEE-50 ampoules) (by Magicine Pharma CO., New Delhi, India. Lot No: DXLL18B24-B),

STG, provided as tablets (JANUVIA 100mg tablets) (by Merck Sharp and Dohme Company, Northumberland, UK. Lot No: S008904.

Urethane: was purchased from Urethane and sourced from Sigma-Aldrich (St. Louis, MO, USA). It was dissolved in saline before use.

2.2. Animals:

This experimental study was achieved using 24 adult male albino rats aged above 2 months and with weights between 180 and 220 g. They were obtained from the animal research center, Faculty of Veterinary Medicine, Benha University. Each of the 4 rats was placed in a separate cage and was fed a standard diet, with free access to food and water. They were placed at room temperature (25 ° C) with a 12:12-h light/dark cycle. These conditions were continued for 10 days before the experiment for acclimatization. The study period lasted for 3 weeks. Experimental rats should be under completely healthy conditions all through the experiment and under the care of a professional technician and a qualified researcher. All procedures were approved by the ethical committee of the Benha Faculty of Medicine (RC 20-12-2024). No rats died throughout the experiment. At the end of the study, the rats were incinerated at Benha University Hospital incinerator.

2.3. Experimental design:

After one week of the acclimatization period, the rats (n=6) were split into four equal groups. Before beginning treatments, there was no discernible variation in

the body weight of the animals in the various groups; the animals were distributed at random. The rats were classified into 4 groups as follows:

Group (I) (Control group), rats were injected with saline intra peritoneal (i.p) (2.5 ml/kg/ day) for 3 weeks [9].

Group (II) STG group was given (10 mg/kg/day) orally by esophageal tube for 3 weeks [10].

Group (III) (DOX group): rats were injected by DOX in a dose of 1mg/kg i.p per day for five injections \ weeks, this is for 3 weeks to produce a cumulative dose of 15mg/kg [11].

Group (IV) (STG +DOX group): The same dose of STG and DOX were given as mentioned before.

2.4. Procedure of the experiments:

After a 12-hour post-treatment period and an overnight fast, rats were given 1.5 g/kg of urethane to induce anesthesia so that their cardiac condition could be monitored by electrocardiogram. The supplier of urethane was Sigma-Aldrich, located in St. Louis, Missouri, USA. The SBP, DBP, Mean BP, and ECG of each rat were recorded at the end of the experiment, then the animals were fixed on an operating table. A craniocaudal incision of about 2 cm was made, parallel with and slightly to the left of the sternum. The blood samples were taken from the aorta, then put into non-heparinized tubes and allowed to clot. The resulting sera were separated using automated pipettes and stored in Eppendorf tubes at -20°C for subsequent biochemical analysis. Then the hearts were excised, washed, and stored. After collecting blood samples, light pressure on the thorax helps to bring the heart outside without damage. The heart was divided longitudinally into two halves. Half was immediately washed with normal saline, frozen in liquid nitrogen, and stored at -80°C. The other half was kept in formaldehyde to be stained with Hematoxylin and Eosin (H&E) and examined for histopathological lesions in the hearts by using a light microscope (Olympus BX-50 Olympus Corporation, Tokyo, Japan).

2.5 ECG and ABP recording:

Typically, for Lead II, the negative electrode should be placed on the right forelimb, the positive electrode on the left hind limb, and the reference (ground) electrode on the right hind limb or another neutral site.

The program Power Lab 4/20 (data collecting system, AD Instruments Pty Ltd, Australia) was connected to the electrodes. The results were computed automatically based on the millivolts of voltage calibration. Continuous electrocardiogram (ECG) monitoring was done by using standard artifact-free lead II. The ECG was used to record the heart rate (beat/min), T waves (mv), and ST depression (12). ABP was measured by carotid artery cannulation using Software Lab Chart 8 power lab recorder and analyzer (AD Instruments, Mountain View, CA, USA) (13).

2.6. Biochemical assessment:

2.6.1 Assessment of cardiotoxicity markers.

Sera were separated from the clotted blood by centrifugation at 5000 rpm for 10 min and stored at -20°C till the assay of CK-MB (a highly reliable biomarker of cardiac injury). It was detected based on a kinetic photometric method using an available commercial kit (Elitech, France). LDH activity was estimated according to standard methods using an available commercial kit (Human Gesellschaft fur Biochemica und Diagnostica, Germany).

2.6.2 Assessment of oxidative stress and inflammatory mediators

Serum SOD activity was determined using a commercial kit Provided by (Kamiya Biomedical Company, California, U.S.A. Lot No: KT-745). Serum malondialdehyde (MDA) was assessed using commercial kits provided by (Abcam Biochemicals, Cambridge Science Park, Cambridge, UK, Lot No: ab118970).

Heart tissue was homogenized in a pH 6–7 phosphate buffer. For fifteen minutes, the homogenized tissue was centrifuged at 10,000 g and 4 °C. The supernatant was utilized to assess the level of TNF- α . TNF- α was measured using a Rat TNF- α ELISA kit (CODE: ELR-TNF α -1; Ray Biotech. Whereas, inflammatory mediators Nuclear Factor Kappa B (NF-kB), was measured using ELISA Kit (Catalog # E-EL-R0674; Elabscience, Texas, USA),

2.6.3 Determination of relative values of cardiac gene expression for caspase-3, NrF2 mRNA, and Keap-1

Total RNA for caspase-3, Keap -1, and NrF2 was extracted from cardiac tissues using a GF-I isolation kit (vivantis, Malaysia). Following the manufacturer's instructions, RNA concentration was measured at 260 nm, and purity was assessed using the absorbance ratio at 260/280 nm with a NanoPhotometer.

The QuantiTect reverse transcription kit (Qiagen Valencia, USA) was used to convert 1 µg of total RNA into single-stranded complementary DNA (cDNA) (14). The mRNA levels of NrF2, Keap-1, and caspase-3 in rat cardiac tissues were quantified using the SensiFAST SYBR® No-ROX Kit (Bioline, USA). Rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a housekeeping gene and internal control. Gene-specific PCR primers (Table 3) were designed using Primer Express 3.0 (Applied Biosystems, USA) based on nucleotide sequences from the Gene Bank. Expression levels were calculated using the standard 11Ct method.

Table 1: Primer sequences and amplicon lengths for Nrf2, Caspas-3, and Keap1 in the target-site PCR for high-throughput sequencing.

Gene	primer sequence	
GAPDH	Forward	5'-TGC CAC TCA GAA GAC TGT GG-3'
	Reverse	5'-GGA TGC AGG GAT GAT GTT CT-3'
Caspase-3	Forward	5'-GGC CGA CTT CCT GTA TGC TT-3'
	Reverse	5'-CGT ACA GTT TCA GCA TGG CG-3'
Keap	Forward	5'-CAGCCCTGTACTCTTCCCTCCTT-3'
	Reverse	5'-TGCATACATCACCGCGTCCC-3'
NrF2	Forward	5'-CAG TCT TCA CCA CCC CTG AT-3'
	Reverse	5'-TTG CTC CAT GTC CTG CTG TA-3'

Nrf2, nuclear factor erythroid-2-like factor -2, GAODH: glyceraldehyde 3-phosphate dehydrogenase, Keap1, Kelch-related

2.6.4 Histopathological examination:

Cardiac tissue samples were immersed in 10% formalin for 48 hours to fixate. Thereafter, 4 µm thick sections were meticulously prepared, processed, and stained using hematoxylin and eosin to examine the histological architecture of the myocardial fibers in detail. The sections were stained with hematoxylin and eosin (H&E) for standard histological analysis and Masson trichrome (MT) to assess collagen fibers, following the procedure outlined by Bancroft and Layton (2013). Slide examination and histomorphometric measurements were conducted using a light microscope (Olympus-Bx; 4500) fitted with a digital camera (Nikon-Coolpix; 4500), with objective lenses magnified at ×10 and ×40.

3. Statistical analysis:

The data were analyzed using the program: Statistical Package for Social Science (SPSS) version 20.0 (SPSS Inc., Chicago, IL, USA, 2000). In the statistical comparison between the different groups, the significance of difference was tested using a one-way analysis of variance (ANOVA) followed by the Least Significant Difference (LSD) test for comparison between every two groups. The p-values < 0.05 were considered statistically significant.

4. RESULTS:

4.1. STG improved DOX-induced cardiotoxicity markers in rats:

According to our findings, Rats injected with DOX (Dox group) showed cardiac tissue injury with elevated serum CK-MB and LDH ($P < 0.05$) in the DOX group compared with the STG group and control group. The rise in these parameters was dramatically inhibited by STG pretreatment in the STG+DOX group (table 2). In contrast, STG ameliorated the DOX-induced myocardial injury, as indicated by the remarkable reversal of the ST segment (Figure 1).

4.2. STG improved the DOX-induced cardiac oxidative stress and inflammation in rats.

Compared to the control group, DOX injection resulted in oxidative stress, which was detected by a substantial rise in cardiac MDA in DOX ($P < 0.05$). Notably, rats that were administrated with STG before DOX injection in group STG+DOX showed a reduction in the MDA level. In contrast, rats in group III that were given DOX exhibited a substantial decrease in SOD levels when compared to the control and STG groups ($P < 0.05$). Serum SOD was significantly improved by the combination of DOX and STG compared to the DOX group ($P < 0.05$) (table 3)

4.3. STG ameliorates DOX-induced cardiac inflammatory markers

One of the main causes of the death of cardiomyocytes and the ensuing heart failure is inflammation. The levels of the proinflammatory cytokines TNF- α in cardiac tissue and the expression of the NF-KB gene were examined for this in (table 3). When DOX was injected into rats, the inflammatory mediators TNF- α significantly increased compared to the control and STG-receiving rats. The combination of DOX and STG significantly reduced TNF- α ($P < 0.05$), suggesting that STG has anti-inflammatory properties. NF-KB was dramatically elevated in the DOX-treated group as compared to the control and STG groups

($P < 0.05$). NF-KB was significantly reduced when STG and DOX were combined, suggesting that STG has a beneficial anti-inflammatory effect.

4.4 STG alleviates cardiovascular hemodynamics associated with DOX-induced myocardial injury.

When comparing the DOX group to the control and STG groups, our study found a significant increase in ST-segment amplitude ($P < 0.05$). The ST amplitude significantly decreased after STG therapy with DOX, with a noteworthy drop in heart rate in the DOX group compared to the control and STG groups ($P < 0.05$). SBP, DBP, and Mean BP all significantly decreased ($P < 0.05$), which was used to measure the cardiac dysfunction of DOX. The DOX+STG group showed a significant improvement in blood pressure measures ($P < 0.05$) (figure 2).

DOX-induced bradycardia in rats with a marked decrease in heart rate compared to control rats ($P < 0.05$) while STG administration in combination with DOX improves the heart rate. Regarding LVEF% %, which represents the volume of blood pumped by the cardiac chambers and the ventricular systolic function, it was notably diminished in the DOX group compared with the control group ($P < 0.05$). STG improved this deterioration in LVEF in rats who received STG with DOX (figure 3).

4.5. STG downregulates both cardiac caspase-3, Keap-1 and upregulates NrF2 gene expression levels

The NrF2 gene expression level decreased in the STG group compared to the control group; however, this increase was not statistically significant. The treated group with STG showed a marked upregulation in NrF2 gene expression levels as compared to the DOX group, which was statistically significant (Fig4 a).

Regarding the caspase-3 gene expression level, the DOX group showed significant upregulation in caspase-3 gene expression as compared to the control group ($p < 0.05$). On the other hand, groups treated with STG showed a significant decrease in caspase-3 gene expression when compared to the DOX group ($p < 0.05$) (Fig. 4b). DOX induction of cardiac toxicity significantly upregulated Keap-1 gene expression ($p < 0.05$) compared with the control group. However, treatment with STG significantly decreased keap-1 gene expression compared with the DOX group (Fig. 4c).

Nuclear factor erythroid 2-related factor 2, which has a regulating role in gene transcription in the cells, dramatically decreased in rats that received Dox compared to normal rats. STG had a protective role as Nrf2 was markedly increased in the DOX+STG group ($P<0.05$). The same observation was detected regarding caspase-3.

4.6. STG ameliorates DOX-induced cardiac histopathological changes

Cardiac sections from different groups were stained with H&E. The Control group showed normal cardiac muscle fiber with central round nuclei and normal striation (Fig.5 a &b). The DOX group showed irregular cardiac muscle fibers with multiple spaces between fibers containing extravasated blood cells and dilated blood vessels. The muscle fibers show vacuolated nuclei with inflammatory cellular infiltration and interstitial edema (Fig.5 c&d). DOX+STG treated group showed regression of histopathological changes but with slightly thickened vessels (Fig. 5 e &f).

Mallory's trichrome stain sectioned from all groups was assessed as follows. In the control and STG groups, collagen fibers were seen mildly between muscle fibers (Fig. 6a & b). Conversely, the DOX-treated group revealed significant collagen fiber deposition between muscle fibers (Fig. 6c). The DOX + STG-treated group revealed minimal collagen fiber deposition between muscle fibers, resembling that of the control group (Fig. 6d).

5. DISCUSSION

Doxorubicin (DOX) is a highly effective anticancer drug however, its use is limited by its cardiotoxicity. Manifestations of its cardiotoxicity vary from arrhythmia, reduced ejection fraction, and cardiomyopathies to heart failure

The present study confirmed the cardiac damage associated with DOX administration. Increased oxidative stress was identified as the main mechanism of DOX-induced cardiotoxicity since several studies reported that DOX can generate ROS by multiple mechanisms in addition to producing downregulation of glutathione peroxidase [15].

Conventional antioxidants failed to prevent DOX-induced cardiac damage, so the search for additional mechanisms was mandatory. Since mitochondria are considered the main target organ for DOX-induced cardiotoxicity and the cardiac muscle is one of the tissues with the highest

mitochondrial-containing tissues, the affection of this organelle will severely impair cardiac function. Multiple factors interact to cause DOX-induced mitochondrial dysfunction, such as impairing the structure and function of mitochondrial Creatine Kinase (CK), opening of mitochondrial permeability transition pores leading to apoptosis, reduction of the activity of cytochrome C oxidase, inhibiting members of sirtuin family, and disturbed mitochondrial iron homeostasis [15].

Nrf2 (nuclear factor erythroid-2 related factor 2) is a transcription factor that, when activated, regulates the expression of several genes responsible for antioxidant defense mechanisms, including the mitochondrial glutathione system, and thus the mitochondria become less vulnerable to damage by ROS [16]. The above fact was proven by the severe oxidative stress and apoptosis observed on deletion of Nrf2 in a model of diabetic bladder dysfunction in mice [17].

The pathogenesis of DOX-induced cardiotoxicity is closely linked to the inhibition of the Nrf2 signaling pathway, so targeting the activation of this pathway is mandatory in opposing its cardiotoxicity [16].

Nrf2 was found to inhibit many aspects related to cardiac damage, such as pathological remodeling and dysfunction, by reducing oxidative stress in several conditions. This occurs probably through a mediator role of Nrf2 in hydrogen sulfide-mediated suppression of oxidative stress. In addition, recently, Nrf2 was found to facilitate the autophagy of some toxic protein aggregates resulting from the accumulation of ROS, which reveals a novel protective mechanism of the Nrf2 signaling pathway [17].

Both the antioxidant and autophagic effects of Nrf2 activation make it a desirable target for the prevention or treatment of DOX-induced cardiotoxicity

On the other hand, iron accumulation is thought to potentiate DOX-induced cardiotoxicity, and DOX can trigger ferroptosis by Nrf2-mediated upregulation of heme-oxygenase1, which catalyzes heme degradation and accumulation of non-heme iron [14]. Therefore, the activation of Nrf2 in DOX-induced cardiotoxicity can be a 2sided weapon one protective and the other potentiating, however, the present study revealed a marked reduction in the expression of Nrf2 concomitant with the administration of DOX and this agrees

with a study that reported an exaggeration of DOX-induced cardiotoxicity in Nrf2 knockout mice [16].

Caspase 3 is a key mediator in apoptosis, which is activated in apoptotic cells by both death ligands and mitochondrial pathways but also shares in non-apoptotic functions such as tissue differentiation, regeneration, and neural development. DOX induces apoptosis through the activation of caspase-3, suggesting that apoptosis has an important role in the progression of DOX-induced cardiotoxicity [18]. Interestingly, this susceptibility to the apoptosis of cardiomyocytes under the effect of DOX decreased from neonatal to adult mice which means that it might be age dependent. In the present study, DOX-induced cardiotoxicity was associated with increased levels of caspase 3 apoptotic enzyme, and this was also confirmed by another study, which recommends that caspase 3 be a surrogate biomarker for DOX-induced cardiotoxicity [19].

Numerous antioxidant pathways, including the Nrf2/Keap1 signaling pathway, are involved in cellular redox homeostasis (4,27). Nrf2/Keap1 regulates the expression levels of antioxidants and phase II detoxification enzymes [20]. (39-41). Nrf2 is highly expressed in tissues where detoxification reactions take place and is a key regulator of the cellular defense mechanism in several organs, including the brain, lung, bladder, kidney, liver, and ovary, as well as macrophages and erythrocytes. The Nrf2/Keap1 signaling pathway maintains the healthy endothelial phenotype under normal physiological conditions. Endothelium is a type of tissue located at the border between blood and tissues and is primarily involved in the regulation of vascular tone, thromboresistivity, inflammation of the vascular wall, and cellular adhesion [21]. Increased ROS production in the endothelium activates Nrf2, which causes increased expression levels of intracellular HO-1, glutathione peroxidase (GPx), GSH, glutamate-cysteine ligase modifier subunit, sulfiredoxin-1, NQO1, protease-activated receptor 4, and oxidative stress-induced growth inhibitor 1 genes in arterial endothelial cells. Studies using animal models have concluded that insufficient levels of Nrf2 in various types of tissue concurrently are associated with susceptibility to several diseases, including cardiovascular disease [22]. Studies investigating the role of the Nrf2/Keap1 signaling pathway

in atherosclerosis, hypertension, myocardial infarction and ischemia have been conducted; however, to the best of our knowledge, there are currently no studies regarding Nrf2/Keap1 signaling in thromboembolism, which is the third leading cause of cardiovascular disease-associated mortality, after coronary artery disease and stroke [19]. In the present study, STG reduces both cardiac caspase-3, and Keap-1 upregulates Nrf2 gene expression levels, and reduces oxidative stress.

The DPP-4 inhibitor, STG, is a widely used medication for the treatment of type 2 diabetes mellitus. Although clinical trials haven't exhibited a significant cardioprotective effect of DPP4 inhibitors and debate exists on its role in preventing heart failure, experimental studies have demonstrated beneficial effects on cardiac myocytes through improving mitochondrial function and inhibition of oxidative stress [22], which makes this drug a potential therapeutic agent against DOX-induced cardiac damage

These findings agreed with **El-Agamy, D. S., et al., [23]**, who reported that when rats were given STG before DOX administration, normal cardiac function was restored. However, a comparative study on whether pre/cotreatment of STG is more effective in reversing DIC is recommended.

STG, when combined with melatonin in diabetic cardiomyopathy, has been proven to improve mitochondrial biogenesis through the sirtuin1 mediated pathway [24], which was found to be suppressed by DOX

In another study, STG reduced oxidative stress and excessive autophagy through the p62-Keap1-Nrf2 signalling pathway and nuclear translocation of Nrf2 in a case of lung injury secondary to severe acute pancreatitis (20). Also, STG activated the Nrf2 pathway in a rat's brain-induced Alzheimer's disease [25].

Another study reported a downregulation of a KEAP 1 inhibitor, which is a negative regulator of Nrf2 activation by STG [26]. All these studies agree with the results of the present study, which revealed an increase in Nrf2 expression on STG administration.

Overall, STG has been shown to have extra protective effects beyond glucose control. Studies indicate that it can reduce caspase-3 expression, thus potentially reducing cell death in various tissues. For example, antifibrotic and

antiapoptotic effects of STG were demonstrated in lung and testicular tissues influencing caspase activity [27]. In the present study, STG reduced the levels of caspase 3 and prevented the activation of NF-kappa B, proving its protective antiapoptotic role in DOX-induced cardiotoxicity.

5. CONCLUSION:

In summary, DOX-induced cardiotoxicity is a fact with a multifactorial etiology of these excessive oxidative stress associated with the suppression of Nrf2 mediated antioxidant defense mechanisms and autophagy of toxic proteins, mitochondrial dysfunction, and increased apoptosis by activation of caspase 3 enzyme revealed. However, the cardiotoxicity is dose-dependent and sitagliptin administration -a DPP4 inhibitor- has shown a protective effect against DOX cardiac damage through decreasing apoptosis and activating the Nrf2 pathway combating the oxidative stress induced by DOX in the heart which makes a potential therapeutic agent against the harmful cardiac effects of DOX, however, the dose of sitagliptin and timing of administration (pre/co) and duration needs to be further investigated to reach optimum protection

6. CONFLICT OF INTEREST:

There is no conflict of interest

Author contributions:

M.M.H. and E.M.K. wrote the main manuscript text. W.H.M. and M.A.E. performed experiments and data analysis. A.Z.E. and M.K.A. assisted in the interpretation of results and manuscript revision. All authors reviewed and approved the final manuscript.

REFERENCE:


1. Xiao K, Luo J, Li Y, Lee JS, Fung G, Lam KS. PEG-oligocholeic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. *J Contr Release*, 155(2), 272–281, 2011.
2. Raj S, Franco SI and Lipshultz SE. Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment. *Current Treatment Options in Cardiovascular Medicine*, 16(6), 315, 2014.
3. Nebigil, C. G., and Laurent, D. Updates in anthracycline-mediated cardiotoxicity. *Front. Pharmacol.* 9, 1–13, doi:10.3389/fphar.01262, 2018.
4. Salazar-Mendiguchía J, González-Costello J, Roca J, Ariza-Solé A, Manito N, Cequier Á. Anthracycline-mediated cardiomyopathy: Basic molecular

- knowledge for the cardiologist. *Archivos de Cardiología de México*, 84(3), 218-223, 2014.
5. Dellapasqua S, Trillo Aliaga P, Munzone E, Bagnardi V, Pagan E, Montagna E, Cancelli G, Ghisini R, Sangalli C, Negri M, Mazza M. "Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial." *Current Oncology (Toronto, Ont.)*, 28 (6), 5167–78, 2021.
6. Bennett, R. G. Sitagliptin. Reference Module in Biomedical Sciences. Elsevier, pp, 1-2, doi:10.1016/b978-0-12-801238-3, 64134-x, 2018.
7. Mundil D, Cameron-Vendrig A and Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. *Diabetes Vasc Dis Res*, 9: 95–108, 2012.
8. Green DR, Kroemer G. The pathophysiology of mitochondrial cell Er E, Oliver L, Cartron PF, Juin P, Manon S, Vallette FM. Mitochondria as the target of the pro-apoptotic protein Bax. *Biochim Biophys Acta*, 1757, 1301–1311, 2006.
9. Kamel, M., Farouk, L., Osman, A., Khorshid, O. and Abdo, M. Comparative Study of the Protective Effect of Metformin and Sitagliptin against Doxorubicin-Induced Cardiotoxicity in Rats. *Clinical Pharmacology & Biopharmaceutics*, 06, <http://doi:10.4172/2167-065X.1000174>, 2017.
10. Dennison CA, Eslinger AJ, Reimer RA. Preconception Prebiotic and Sitagliptin Treatment in Obese Rats Affects Pregnancy Outcomes and Offspring Microbiota, Adiposity, and Glycemia. *Front Endocrinol (Lausanne)*. 2017 Oct 30; 8:301. doi: 10.3389/fendo.2017.
11. Hekmat AS, Navabi Z, Alipanah H, Javanmardi K. Alamandine significantly reduces doxorubicin-induced cardiotoxicity in rats. *Human & Experimental Toxicology*. Oct;40(10):1781-95. DOI: 10.1177/09603271211010896, 2021
12. Romito G, Castagna P, Sabetti MC, Ablondi M, Cipone M. Evaluating the accuracy of a six- lead smartphone- based electrocardiographic device compared with standard electrocardiography in brachymorphic dogs. *Veterinary Record*. Oct 7;193(7):no-.DOI: 10.1002/vetr.2879,2023
13. Alzahrani AA, Cao LL, Aldossary HS, Nathanael D, Fu J, Ray CJ, Brain KL, Kumar P, Coney AM, Holmes AP. β -Adrenoceptor blockade prevents carotid body hyperactivity and elevated vascular sympathetic nerve density induced by chronic intermittent hypoxia. *Pflügers Archiv-European Journal of Physiology*. Jan; 473:37-51,2021.
14. Dafforn A, Chen P, Deng G, Herrler M, Iglehart D, Koritala S, Lato S, Pillarisetty S, Purohit R, Wang M, Wang S. Linear mRNA amplification from as little as 5 ng total RNA for global gene expression analysis. *Biotechniques*. Nov 1;37(5):854-7,2004.
15. Wu, Bin Bin, Kam Tong Leung, and Ellen Ngar-Yun Poon. "Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity." *International Journal of Molecular Sciences* 23, no, 3 (February 9), 1912, <https://doi.org/10.3390/ijms23031912>, 2022.
16. Ahmed, Syed Minhaj Uddin, Lin Luo, Akhileshwar Namani, Xiu Jun Wang, and Xiuwen Tang. "Nrf2 Signaling Pathway: Pivotal Roles in Inflammation." *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 1863, no, 2 (February 1), 585–97, <https://doi.org/10.1016/j.bbadis.2016.11.005>, 2017.
17. Wang, Lei, Weiaho Sun, Guanyu Ren, Yi Sun, Cheng Xu, Qixiang Song, Xinhui Zhang, Chenghua Yang, and Zhiyong Liu. "Deletion of Nrf2 Induced Severe Oxidative Stress and Apoptosis in Mice Model of Diabetic Bladder Dysfunction." *International Urology and Nephrology* 56, no, 10, 3231–40, <https://doi.org/10.1007/s11255-024-04064-y>, 2024.

18. Ueno, Michihiko, Yoshihiko Kakinuma, Koh-ichi Yuhki, Nobuyuki Murakoshi, Motoyuki Iemitsu, Takashi Miyauchi, and Iwao Yamaguchi. "Doxorubicin Induces Apoptosis by Activation of Caspase-3 in Cultured Cardiomyocytes in Vitro and Rat Cardiac Ventricles in Vivo." *Journal of Pharmacological Sciences* 101, no. 2 (June), 151–58, <https://doi.org/10.1254/jphs.fp0050980>, 2006.
19. Al-Kuraishy, Hayder M., and Reem Ghanim Hussein. "Caspase-3 Levels (CASP-3) in Doxorubicin Induced-Cardiotoxicity: Role of Metformin Pretreatment." *Research Journal of Oncology* 1, no. 1 (n.d.), 0–0, 2016.
20. Li C, Cheng L, Wu H, He P, Zhang Y, Yang Y, Chen J and Chen M: Activation of the KEAP1- NRF2- ARE signaling pathway reduces oxidative stress in Hep2 cells. *Mol Med Rep* 18: 2541-2550, 2018. Zhou, Yutong, Wendong Suo, Xinai Zhang, Jiaojiao Liang, Weizhe Zhao, Yue Wang, Hong Li, and Qing Ni. "Targeting Mitochondrial Quality Control for Diabetic Cardiomyopathy: Therapeutic Potential of Hypoglycemic Drugs." *Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie*, 168, (December), 115669, <https://doi.org/10.1016/j.biopha.2023.115669>, 2023.
21. Vanhoutte PM, Shimokawa H, Feletou M and Tang EH: Endothelial dysfunction and vascular disease - a 30th anni-versary update. *Acta Physiol (Oxf)* 219: 22-96, 2017
22. Sarutipai boon I, Settasatian N, Komanasin N, Kukongwiri yapan U, Sawanyawisuth K, Intharaphet P, Senthong V and Settasatian C: Association of Genetic Variations in NRF2, NQO1, HMOX1, and MT with severity of coronary artery disease and related risk factors. *Cardiovasc Toxicol* 20: 176-189, 2020.
23. Dina S El-Agamy, Hany M Abo-Haded and Mohamed A Elkablawy. Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats. *Experimental Biology and Medicine*, 241, 1577–1587, Original doi, <https://doi.org/10.1177/1535370216643418>, 2016.
24. Kong, Lingming, Jie Deng, Xiang Zhou, Binbin Cai, Baofu Zhang, Xiaohu Chen, Zongjing Chen, and Weiming Wang. "Sitagliptin Activates the P62-Keap1-Nrf2 Signalling Pathway to Alleviate Oxidative Stress and Excessive Autophagy in Severe Acute Pancreatitis-Related Acute Lung Injury." *Cell Death & Disease* 12, no. 10 (October 11), 928, <https://doi.org/10.1038/s41419-021-04227-0>, 2021.
25. Song, Ronggang, Jing Ren, Junxia Sun, and Ming Li. "Melatonin Postconditioning Combined with Sitagliptin Exerts Full Cardioprotection in Diabetic Hearts of Aged Rats through an AMPK-Dependent Mechanism." *Archives of Biological Sciences* 73, no. 1 (March 19), 83–92, <https://doi.org/10.2298/ABS210111004S>, 2021.
26. Villavicencio-Tejo, Francisca, Margrethe A. Olesen, Alejandra Aránguiz, and Rodrigo A. Quintanilla. "Activation of the Nrf2 Pathway Prevents Mitochondrial Dysfunction Induced by Caspase-3 Cleaved Tau: Implications for Alzheimer's Disease." *Antioxidants* 11, no. 3 (March), 515, <https://doi.org/10.3390/antiox11030515>, 2022.
27. Jiang, Weidong, Dacheng Wen, Zhaohua Cheng, Yongsheng Yang, Ge Zheng, and Fangying Yin. "Effect of Sitagliptin, a DPP-4 Inhibitor, against DENA-Induced Liver Cancer in Rats Mediated via NF-κB Activation and Inflammatory Cytokines." *Journal of Biochemical and Molecular Toxicology* 32, no. 12 (December), e22220, <https://doi.org/10.1002/jbt.22220>, 2018.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1: Primer sequences and amplicon lengths for Nrf2, Caspase-3, and Keap1 in the target-site PCR for high-throughput sequencing.

Gene	primers	
GAPDH	Forward	5'-TGC CAC TCA GAA GAC TGT GG-3'
	Reverse	5'-GGA TGC AGG GAT GAT GTT CT-3'
Caspase-3	Forward	5'-GGC CGA CTT CCT GTA TGC TT-3'
	Reverse	5'-CGT ACA GTT TCA GCA TGG CG-3'
Keap	Forward	5'-CAGCCCTGTACTCTTCCCTCCTT-3'
	Reverse	5'-TGCATACATCACCGCGTCCC-3'
Nrf2	Forward	5'-CAG TCT TCA CCA CCC CTG AT-3'
	Reverse	5'-TTG CTC CAT GTC CTG CTG TA-3'

Nrf2, nuclear factor erythroid-2-like factor -2, GAODH: glyceraldehyde 3-phosphate dehydrogenase, Keap1, Kelch-related

Table (2): Evaluation of cardiac enzymes

Groups	Control group (I)	STG group (II)	DOX group (III)	DOX + STG group (IV)
CK-MB(U/L)	314.67 ± 35.16	311.567 ± 34.15	602.83 ± 37.15 ^{a, b}	317.54 ± 31.16 ^c
LDH (μU)	197 ± 15.28	199 ± 14.18	318 ± 26.75 ^{a, b}	201.17 ± 18.50 ^c

DOX: Doxorubicin; STG: sitagliptin; CK-MB: Creatine phosphokinase; LDH: lactate dehydrogenase, Data are represented as Mean ± SD., n=8. P < 0.05 is significantly tested by ANOVA and post hoc multiple comparison LSD method. a: P < 0.05 vs. Control group; b: P < 0.05vs STG group, c: P < 0.05vs. DOX group

Table (3): Assessment of oxidative stress and inflammatory markers

Groups	Control group (I)	STG group (II)	DOX group (III)	DOX + STG group (IV)
SOD (U/mL)	14.13 ± 2.97	15.22 ± 2.97	6.32 ± 1.47 ^{a, b}	19.70 ± 1.84
MDA (nmol/mL)	1.90 ± 0.40	1.95 ± 0.30	3.21 ± 0.60 ^{a, b}	1.26 ± 0.24 ^{a, b, c}
TNF-α (pg/ mg protein)	1.95 ± 0.58	2.234 ± 0.61	7.33 ± 2.07 ^{a, c}	2.3 ± 0.19 ^{a, b, c}
NF-KB (pg/mg protein)	58.52 ± 4.52	58.54 ± 5.70	168.37 ± 4.87 ^{a, b}	85.67 ± 16.56 ^{a, b, c}

DOX: Doxorubicin; STG: sitagliptin; SOD: superoxide dismutase enzyme. MDA; Malondialdehyde, TNF- α : tumor necrotic factor - α , NF-KB: nuclear factor-kappa B, Data are represented as Mean $\pm$ SD., n=8. P < 0.05 is significant tested by ANOVA and post hoc multiple comparison LSD method. a: P < 0.05 vs. Control group; b: P < 0.05vs STG group, c: P < 0.05vs. DOX group

For Peer Review